SYT7-based Therapies for Prostate Cancer (G9066)

Target Name: SYT7

NCBI ID: G9066

SYT7

SYT7-based Therapies for Prostate Cancer

Prostate cancer is a leading cause of cancer death in men worldwide, with an estimated 97,000 new cases and 6,500 deaths in the United States alone in 2020. Despite advances in cancer treatment, the survival rate for prostate cancer remains poor, with a five-year survival rate of only around 27%.

One potential solution to this problem is the targeting of SYT7, a protein that is expressed in high levels in prostate cancer cells. Researchers have identified that SYT7 is involved in the development and progression of prostate cancer, and that it may be a useful drug target or biomarker for this disease.

SYT7 is a transmembrane protein that is expressed in a variety of tissues, including the brain, pancreas, and gastrointestinal tract. It is involved in the regulation of cell signaling pathways, and is thought to play a role in the development and progression of many types of cancer.

In the context of prostate cancer, SYT7 is expressed in high levels in the cancer cells and has been shown to be involved in the development and progression of prostate cancer. For example, studies have shown that patients with advanced prostate cancer have lower levels of SYT7 than those with early-stage disease. Additionally, researchers have found that inhibiting SYT7 has been shown to be effective in slowing the growth of prostate cancer tumors.

Despite these promising findings, much more research is needed to fully understand the role of SYT7 in the development and progression of prostate cancer. Researchers are currently seeking to develop SYT7-based therapies as potential treatments for this disease.

One approach that is being explored is the use of small molecules to inhibit SYT7. Researchers have identified a number of small molecules that have been shown to inhibit the activity of SYT7, and are using these molecules to develop potential therapies for prostate cancer. These small molecules are typically applied directly to the cancer cells, and have been shown to be effective in slowing the growth of the tumors.

Another approach that is being explored is the use of antibodies to target SYT7. Researchers have identified antibodies that are specific for SYT7, and are using these antibodies to deliver the antibodies directly to the cancer cells. This approach has the advantage of being able to selectively target the cancer cells, rather than the entire organism.

While the development of SYT7-based therapies for prostate cancer is an promising area of research, there are also concerns about the potential side effects of these therapies. For example, some researchers have suggested that the use of small molecules to inhibit SYT7 may be associated with an increased risk of side effects, such as nausea and vomiting. Additionally, the use of antibodies to target SYT7 may be associated with an increased risk of allergic reactions and anaphylaxis.

Despite these concerns, the development of SYT7-based therapies for prostate cancer is a promising area of research that has the potential to improve the treatment outcomes for this disease. Further research is needed to fully understand the role of SYT7 in the development and progression of prostate cancer, and to develop safe and effective therapies based on this protein.

Protein Name: Synaptotagmin 7

Functions: Ca(2+) sensor involved in Ca(2+)-dependent exocytosis of secretory and synaptic vesicles through Ca(2+) and phospholipid binding to the C2 domain (By similarity). Ca(2+) induces binding of the C2-domains to phospholipid membranes and to assembled SNARE-complexes; both actions contribute to triggering exocytosis (By similarity). SYT7 binds Ca(2+) with high affinity and slow kinetics compared to other synaptotagmins (By similarity). Involved in Ca(2+)-triggered lysosomal exocytosis, a major component of the plasma membrane repair (PubMed:11342594). Ca(2+)-regulated delivery of lysosomal membranes to the cell surface is also involved in the phagocytic uptake of particles by macrophages (By similarity). Ca(2+)-triggered lysosomal exocytosis also plays a role in bone remodeling by regulating secretory pathways in osteoclasts and osteoblasts (By similarity). In case of infection, involved in participates cell invasion by Trypanosoma cruzi via Ca(2+)-triggered lysosomal exocytosis (PubMed:11342594, PubMed:15811535). Involved in cholesterol transport from lysosome to peroxisome by promoting membrane contacts between lysosomes and peroxisomes: probably acts by promoting vesicle fusion by binding phosphatidylinositol-4,5-bisphosphate on peroxisomal membranes (By similarity). Acts as a key mediator of synaptic facilitation, a process also named short-term synaptic potentiation: synaptic facilitation takes place at synapses with a low initial release probability and is caused by influx of Ca(2+) into the axon terminal after spike generation, increasing the release probability of neurotransmitters (By similarity). Probably mediates synaptic facilitation by directly increasing the probability of release (By similarity). May also contribute to synaptic facilitation by regulating synaptic vesicle replenishment, a process required to ensure that synaptic vesicles are ready for the arrival of the next action potential: SYT7 is required for synaptic vesicle replenishment by acting as a sensor for Ca(2+) and by forming a complex with calmodulin (By similarity). Also acts as a regulator of Ca(2+)-dependent insulin and glucagon secretion in beta-cells (By similarity). Triggers exocytosis by promoting fusion pore opening and fusion pore expansion in chromaffin cells (By similarity). Also regulates the secretion of some non-synaptic secretory granules of specialized cells (By similarity)

The "SYT7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYT7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets